CollPlant Bio (CLGN) Stock Forecast, Price Target & Predictions
CLGN Stock Forecast
CollPlant Bio stock forecast is as follows: an average price target of $14.00 (represents a 188.66% upside from CLGN’s last price of $4.85) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
CLGN Price Target
The average price target for CollPlant Bio (CLGN) is $14.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 188.66% upside from CLGN's last price of $4.85.
CLGN Analyst Ratings
According to 1 Wall Street analysts, CollPlant Bio's rating consensus is 'Buy'. The analyst rating breakdown for CLGN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
CollPlant Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 05, 2024 | Jason Kolbert | EF Hutton | $14.00 | $4.65 | 201.08% | 188.66% |
The latest CollPlant Bio stock forecast, released on Aug 05, 2024 by Jason Kolbert from EF Hutton, set a price target of $14.00, which represents a 201.08% increase from the stock price at the time of the forecast ($4.65), and a 188.66% increase from CLGN last price ($4.85).
CollPlant Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $14.00 | $14.00 |
| Last Closing Price | $4.85 | $4.85 | $4.85 |
| Upside/Downside | -100.00% | 188.66% | 188.66% |
In the current month, the average price target of CollPlant Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CollPlant Bio's last price of $4.85. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 21, 2024 | EF Hutton | Underperform | Underperform | Hold |
| Aug 21, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 05, 2024 | EF Hutton | - | Buy | Initialise |
CollPlant Bio's last stock rating was published by EF Hutton on Aug 21, 2024. The company gave CLGN a "Underperform" rating, the same as its previous rate.
CollPlant Bio Financial Forecast
CollPlant Bio Revenue Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $433.00K | $58.00K | $109.00K | $66.00K | $66.00K | - | $140.00K |
| Avg Forecast | $4.05M | $3.90M | $3.60M | $3.45M | $2.29M | $2.21M | $2.04M | $1.96M | $4.86M | $4.68M | $4.32M | $4.14M | $2.50M | $2.35M | $6.38M | $1.77M | $432.00K | $416.00K | $395.50K | $642.00K | $8.56M | $3.50M | $3.59M | $238.33K | $100.00K | $3.10M | $2.86M | $2.74M | $338.00K | $246.00K |
| High Forecast | $7.04M | $6.78M | $6.26M | $6.00M | $3.99M | $3.84M | $3.55M | $3.40M | $8.45M | $8.13M | $7.51M | $7.20M | $4.35M | $4.08M | $11.09M | $3.08M | $750.86K | $723.05K | $687.42K | $1.12M | $14.89M | $6.09M | $6.24M | $414.25K | $173.81K | $5.38M | $2.86M | $4.32M | $533.68K | $388.42K |
| Low Forecast | $964.28K | $928.57K | $857.14K | $821.43K | $546.43K | $526.19K | $485.71K | $465.48K | $1.16M | $1.11M | $1.03M | $985.71K | $595.83K | $558.33K | $1.52M | $422.02K | $102.86K | $99.05K | $94.17K | $152.86K | $2.04M | $833.81K | $855.16K | $56.74K | $23.81K | $736.90K | $2.86M | $1.22M | $151.21K | $110.05K |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.82% | 0.58% | 0.04% | 0.02% | 0.02% | - | 0.57% |
CollPlant Bio's average Quarter revenue forecast for Jun 23 based on 0 analysts is $3.59M, with a low forecast of $855.16K, and a high forecast of $6.24M. CLGN's average Quarter revenue forecast represents a 729.48% increase compared to the company's last Quarter revenue of $433.00K (Mar 23).
CollPlant Bio EBITDA Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.24M | $-4.38M | $-4.19M | $-3.92M | $-3.53M | - | $-2.87M |
| Avg Forecast | $-2.70M | $-2.60M | $-2.40M | $-2.30M | $-1.53M | $-1.47M | $-1.36M | $-1.30M | $-3.24M | $-3.12M | $-2.88M | $-2.76M | $-1.67M | $-1.56M | $-4.25M | $-1.18M | $-287.62K | $-276.97K | $-263.32K | $-427.44K | $-5.70M | $-2.33M | $-2.39M | $-158.68K | $-66.58K | $-2.06M | $-1.90M | $-1.88M | $-231.82K | $-2.77M |
| High Forecast | $-642.01K | $-618.24K | $-570.68K | $-546.90K | $-363.81K | $-350.33K | $-323.38K | $-309.91K | $-770.42K | $-741.88K | $-684.82K | $-656.28K | $-396.70K | $-371.73K | $-1.01M | $-280.98K | $-68.48K | $-65.94K | $-62.70K | $-101.77K | $-1.36M | $-555.14K | $-569.36K | $-37.78K | $-15.85K | $-490.63K | $-1.90M | $-840.11K | $-103.71K | $-2.22M |
| Low Forecast | $-4.69M | $-4.51M | $-4.17M | $-3.99M | $-2.66M | $-2.56M | $-2.36M | $-2.26M | $-5.62M | $-5.42M | $-5.00M | $-4.79M | $-2.90M | $-2.71M | $-7.38M | $-2.05M | $-499.92K | $-481.40K | $-457.68K | $-742.93K | $-9.91M | $-4.05M | $-4.16M | $-275.80K | $-115.72K | $-3.58M | $-1.90M | $-2.97M | $-366.03K | $-3.32M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.41% | 65.82% | 2.03% | 2.06% | 1.88% | - | 1.04% |
undefined analysts predict CLGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than CollPlant Bio's previous annual EBITDA (undefined) of $NaN.
CollPlant Bio Net Income Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-3.91M | $-4.13M | $-4.29M | $-4.38M | $-3.95M | - | $-3.08M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $-3.55M | $-3.55M | $3.32M | $-4.24M | $-3.15M | $-3.26M | $-3.09M | $-4.01M | $2.75M | $-1.49M | $-954.54K | $-3.32M | $-3.61M | $-3.55M | $-916.25K | $-1.60M | $-3.32M | $-2.97M |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $-33.82K | $-33.82K | $6.51M | $-40.36K | $-30.00K | $-31.09K | $-29.45K | $-38.18K | $5.39M | $-14.18K | $-9.09K | $-31.64K | $-34.36K | $-33.82K | $-916.25K | $-451.10K | $-934.41K | $-2.37M |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $-6.96M | $-6.96M | $31.64K | $-8.30M | $-6.17M | $-6.40M | $-6.06M | $-7.86M | $26.18K | $-2.92M | $-1.87M | $-6.51M | $-7.07M | $-6.96M | $-916.25K | $-2.81M | $-5.82M | $-3.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.18% | 1.14% | 1.21% | 4.79% | 2.47% | - | 1.04% |
CollPlant Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CLGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
CollPlant Bio SG&A Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.52M | $2.04M | $1.54M | $1.61M | $1.56M | - | $1.18M |
| Avg Forecast | $20.81M | $20.04M | $18.50M | $17.73M | $11.79M | $11.36M | $10.48M | $10.05M | $24.98M | $24.05M | $22.20M | $21.28M | $12.86M | $12.05M | $32.79M | $9.11M | $2.22M | $2.14M | $2.03M | $3.30M | $44.01M | $18.00M | $18.46M | $1.22M | $513.90K | $15.91M | $14.68M | $14.20M | $1.75M | $1.28M |
| High Forecast | $36.18M | $34.84M | $32.16M | $30.82M | $20.50M | $19.74M | $18.22M | $17.46M | $43.41M | $41.80M | $38.59M | $36.98M | $22.35M | $20.95M | $56.99M | $15.83M | $3.86M | $3.72M | $3.53M | $5.73M | $76.50M | $31.28M | $32.08M | $2.13M | $893.21K | $27.65M | $14.68M | $22.43M | $2.77M | $2.01M |
| Low Forecast | $4.96M | $4.77M | $4.40M | $4.22M | $2.81M | $2.70M | $2.50M | $2.39M | $5.95M | $5.73M | $5.29M | $5.07M | $3.06M | $2.87M | $7.81M | $2.17M | $528.59K | $509.01K | $483.92K | $785.54K | $10.48M | $4.28M | $4.39M | $291.62K | $122.36K | $3.79M | $14.68M | $6.35M | $784.36K | $570.87K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.25% | 3.96% | 0.10% | 0.11% | 0.11% | - | 0.93% |
CollPlant Bio's average Quarter SG&A projection for Jun 23 is $18.46M, based on 0 Wall Street analysts, with a range of $4.39M to $32.08M. The forecast indicates a 1110.35% rise compared to CLGN last annual SG&A of $1.52M (Mar 23).
CollPlant Bio EPS Forecast
| Dec 28 | Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | 1 | - | - | - | - | - | - | - | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.35 | $-0.37 | $-0.39 | $-0.40 | $-0.37 | - | $-0.29 |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $-0.31 | $-0.31 | $0.29 | $-0.37 | $-0.28 | $-0.28 | $-0.27 | $-0.35 | $0.24 | $-0.13 | $-0.08 | $-0.29 | $-0.32 | $-0.31 | $-0.08 | $-0.14 | $-0.29 | $-0.28 |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.00 | $0.57 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $0.47 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $-0.08 | $-0.04 | $-0.08 | $-0.08 |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $-0.61 | $-0.61 | - | $-0.73 | $-0.54 | $-0.56 | $-0.53 | $-0.69 | - | $-0.25 | $-0.16 | $-0.57 | $-0.62 | $-0.61 | $-0.08 | $-0.25 | $-0.51 | $-0.49 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.21% | 1.17% | 1.26% | 5.00% | 2.64% | - | 1.04% |
According to undefined Wall Street analysts, CollPlant Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CLGN previous annual EPS of $NaN (undefined).
CollPlant Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.66 | $20.00 | 1104.82% | Buy |
| MOLN | Molecular Partners | $5.08 | $29.00 | 470.87% | Buy |
| XCUR | Exicure | $2.21 | $12.00 | 442.99% | - |
| STTK | Shattuck Labs | $3.75 | $12.00 | 220.00% | Buy |
| PRTC | PureTech Health | $19.59 | $57.00 | 190.96% | Buy |
| CLGN | CollPlant Bio | $4.85 | $14.00 | 188.66% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.27 | $6.00 | 164.32% | Buy |
| PRLD | Prelude Therapeutics | $2.45 | $6.25 | 155.10% | Sell |
| NAMS | NewAmsterdam Pharma Company | $15.45 | $36.00 | 133.01% | Buy |
| REPL | Replimune Group | $11.03 | $24.20 | 119.40% | Buy |
| KROS | Keros Therapeutics | $55.04 | $105.00 | 90.77% | Buy |
| CCCC | C4 Therapeutics | $6.46 | $11.33 | 75.39% | Hold |
| ELYM | Eliem Therapeutics | $7.96 | $13.00 | 63.32% | Buy |
| MRUS | Merus | $50.10 | $77.86 | 55.41% | Buy |
| CRNX | Crinetics Pharmaceuticals | $52.99 | $70.14 | 32.36% | Buy |
| VCEL | Vericel | $44.32 | $57.33 | 29.35% | Buy |
| IKNA | Ikena Oncology | $1.67 | $1.33 | -20.36% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
CLGN Forecast FAQ
Is CollPlant Bio a good buy?
Yes, according to 1 Wall Street analysts, CollPlant Bio (CLGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CLGN's total ratings.
What is CLGN's price target?
CollPlant Bio (CLGN) average price target is $14 with a range of $14 to $14, implying a 188.66% from its last price of $4.85. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will CollPlant Bio stock go up soon?
According to Wall Street analysts' prediction for CLGN stock, the company can go up by 188.66% (from the last price of $4.85 to the average price target of $14), up by 188.66% based on the highest stock price target, and up by 188.66% based on the lowest stock price target.
Can CollPlant Bio stock reach $7?
CLGN's average twelve months analyst stock price target of $14 supports the claim that CollPlant Bio can reach $7 in the near future.
What are CollPlant Bio's analysts' financial forecasts?
CollPlant Bio's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $8.5M (high $14.77M, low $2.02M), average EBITDA is $-5.659M (high $-1.347M, low $-9.836M), average net income is $0 (high $0, low $0), average SG&A $43.68M (high $75.92M, low $10.4M), and average EPS is $0 (high $0, low $0). CLGN's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $15M (high $26.07M, low $3.57M), average EBITDA is $-9.987M (high $-2.378M, low $-17.358M), average net income is $0 (high $0, low $0), average SG&A $77.09M (high $133.98M, low $18.35M), and average EPS is $0 (high $0, low $0).
Did the CLGN's actual financial results beat the analysts' financial forecasts?
Based on CollPlant Bio's last annual report (Dec 2022), the company's revenue was $299K, which missed the average analysts forecast of $8.79M by -96.60%. Apple's EBITDA was $-16.021M, beating the average prediction of $-5.907M by 171.21%. The company's net income was $-16.753M, beating the average estimation of $-9.677M by 73.12%. Apple's SG&A was $6.74M, missing the average forecast of $45.3M by -85.12%. Lastly, the company's EPS was $-1.52, beating the average prediction of $-0.845 by 79.88%. In terms of the last quarterly report (Mar 2023), CollPlant Bio's revenue was $433K, beating the average analysts' forecast of $238.33K by 81.68%. The company's EBITDA was $-3.239M, beating the average prediction of $-159K by 1941.22%. CollPlant Bio's net income was $-3.911M, beating the average estimation of $-3.322M by 17.74%. The company's SG&A was $1.52M, beating the average forecast of $1.22M by 24.51%. Lastly, the company's EPS was $-0.35, beating the average prediction of $-0.29 by 20.69%